Influenza

Study of a Pandemic Influenza Vaccine

NCT00136331 | PHASE 1 | INTERVENTIONAL

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is the leading candidate to cause the next avian influenza pandemic. This study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in healthy adults.

2 Sites

400 Participants

Recruiting

18 Years to 45 Years

If interested, contact clinicaltrials@cslbehring.com for more information

CSL Behring respects your privacy. For an explanation of how CSL Behring will use the information you are submitting, please view our Privacy Policy

Find closest sites:

SUBMIT

CMAX, a division of IDT Australia

Adelaide,South Australia,Australia,5000

Murdoch Childrens Research Institute

Melbourne,Victoria,Australia,3052

Study Eligibility Criteria

Inclusion Criteria

* Healthy adults

Exclusion Criteria

* History of Guillain-Barre syndrome or active neurological disease

Additional Studies

Additional studies can be found at ClinicalTrials.gov